TY - JOUR
T1 - Development of an individual fitness score (IFS) based on the depression treatment guidelines of in the Japanese Society of Mood Disorders
AU - Fukumoto, Kentaro
AU - Kodaka, Fumitoshi
AU - Hasegawa, Naomi
AU - Muraoka, Hiroyuki
AU - Hori, Hikaru
AU - Ichihashi, Kayo
AU - Yasuda, Yuka
AU - Iida, Hitoshi
AU - Ohi, Kazutaka
AU - Ochi, Shinichiro
AU - Ide, Kenta
AU - Hashimoto, Naoki
AU - Usami, Masahide
AU - Nakamura, Toshinori
AU - Komatsu, Hiroshi
AU - Okada, Tsuyoshi
AU - Nagasawa, Tatsuya
AU - Furihata, Ryuji
AU - Atake, Kiyokazu
AU - Kido, Mikio
AU - Kikuchi, Saya
AU - Yamagata, Hirotaka
AU - Kishimoto, Taishiro
AU - Makinodan, Manabu
AU - Horai, Tadasu
AU - Takeshima, Masahiro
AU - Kubota, Chika
AU - Asami, Takeshi
AU - Katsumoto, Eiichi
AU - Hishimoto, Akitoyo
AU - Onitsuka, Toshiaki
AU - Matsumoto, Junya
AU - Miura, Kenichiro
AU - Yamada, Hisashi
AU - Yasui-Furukori, Norio
AU - Watanabe, Koichiro
AU - Inada, Ken
AU - Otsuka, Kotaro
AU - Hashimoto, Ryota
N1 - Funding Information:
This work was supported by the Japan Agency for Medical Research and Development (AMED) under Grant Number JP16dk0307060, JP19dk0307083, and JP22dk0307112, JSPS KAKENHI Grant Number JP21K17261, the Health and Labor Sciences Research Grants (H29‐Seishin‐Ippan‐001, 19GC1201), the Japanese Society of Neuropsychopharmacology, the Japanese Society of Mood Disorders, the Japanese Society of Clinical Neuropsychopharmacology, the Japanese Society of Psychiatry and Neurology. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Publisher Copyright:
© 2022 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.
PY - 2023/3
Y1 - 2023/3
N2 - Aim: Treatment guidelines are designed to assist patients and health care providers and are used as tools for making treatment decisions in clinical situations. The treatment guidelines of the Japanese Society of Mood Disorders establish treatment recommendations for each severity of depression. The individual fitness score (IFS) was developed as a simple and objective indicator to assess whether individual patients are practicing treatment by the recommendations of the depression treatment guidelines of the Japanese Society of Mood Disorders. Methods: The EGUIDE project members determined the IFS through the modified Delphi method. In this article, the IFS was calculated based on the treatment of depressed patients treated and discharged between 2016 and 2020 at facilities participating in the EGUIDE project. In addition, we compared scores at admission and discharge. Results: The study included 428 depressed patients (mild n = 22, moderate/severe n = 331, psychotic n = 75) at 57 facilities. The mean IFS scores by severity were statistically significantly higher at discharge than at admission with moderate/severe depression (mild 36.1 ± 34.2 vs. 41.6 ± 36.9, p = 0.49; moderate/severe 50.2 ± 33.6 vs. 55.7 ± 32.6, p = 2.1 × 10–3; psychotic 47.4 ± 32.9 versus 52.9 ± 36.0, p = 0.23). Conclusion: We developed the IFS based on the depression treatment guideline, which enables us to objectively determine how close the treatment is to the guideline at the time of evaluation in individual cases. Therefore, the IFS may influence guideline-oriented treatment behavior and lead to the equalization of depression treatment in Japan, including pharmacotherapy.
AB - Aim: Treatment guidelines are designed to assist patients and health care providers and are used as tools for making treatment decisions in clinical situations. The treatment guidelines of the Japanese Society of Mood Disorders establish treatment recommendations for each severity of depression. The individual fitness score (IFS) was developed as a simple and objective indicator to assess whether individual patients are practicing treatment by the recommendations of the depression treatment guidelines of the Japanese Society of Mood Disorders. Methods: The EGUIDE project members determined the IFS through the modified Delphi method. In this article, the IFS was calculated based on the treatment of depressed patients treated and discharged between 2016 and 2020 at facilities participating in the EGUIDE project. In addition, we compared scores at admission and discharge. Results: The study included 428 depressed patients (mild n = 22, moderate/severe n = 331, psychotic n = 75) at 57 facilities. The mean IFS scores by severity were statistically significantly higher at discharge than at admission with moderate/severe depression (mild 36.1 ± 34.2 vs. 41.6 ± 36.9, p = 0.49; moderate/severe 50.2 ± 33.6 vs. 55.7 ± 32.6, p = 2.1 × 10–3; psychotic 47.4 ± 32.9 versus 52.9 ± 36.0, p = 0.23). Conclusion: We developed the IFS based on the depression treatment guideline, which enables us to objectively determine how close the treatment is to the guideline at the time of evaluation in individual cases. Therefore, the IFS may influence guideline-oriented treatment behavior and lead to the equalization of depression treatment in Japan, including pharmacotherapy.
UR - http://www.scopus.com/inward/record.url?scp=85142212027&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85142212027&partnerID=8YFLogxK
U2 - 10.1002/npr2.12301
DO - 10.1002/npr2.12301
M3 - Article
C2 - 36394160
AN - SCOPUS:85142212027
SN - 2574-173X
VL - 43
SP - 33
EP - 39
JO - Neuropsychopharmacology Reports
JF - Neuropsychopharmacology Reports
IS - 1
ER -